PharmaShots | Incisive News in 3 Shots

Subscribe Now

mitsubishi tanabe pharma

Mitsubishi Tanabe Pharma America Reports 48-Week P-III Trial (MT-1186-A01) Results of Radicava ORS (edaravone) for Amyotrophic Lateral Sclerosis

Mitsubishi Tanabe Pharma America Reports 48-Week P-III Trial (MT-1186-A01) Results of Radicava ORS (edaravone) for Amyotrophic Lat...

February 28, 2023

Top 20 Immunology Companies Based on 2021 Immunology Segment Total Revenue

Top 20 Immunology Companies Based on 2021 Immunology Segment Total Revenue

August 11, 2022

Mitsubishi Tanabe Pharma Reports US FDA Acceptance of NDA for Edaravone (MT-1186) for the Treatment of ALS

Mitsubishi Tanabe Pharma Reports US FDA Acceptance of NDA for Edaravone (MT-1186) for the Treatment of ALS

January 13, 2022

Top 20 Immunology Companies Based on 2020 Immunology Segment Revenue

Top 20 Immunology Companies Based on 2020 Immunology Segment Revenue

August 12, 2021

Top 20 Immunology Companies Based 2019 Immunology Segment Revenue

Top 20 Immunology Companies Based 2019 Immunology Segment Revenue

October 22, 2020

PharmaShots' Most Read News of 2019

PharmaShots' Most Read News of 2019

January 10, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us